Breast cancer prevention by antihormones and other drugs. Where do we stand?

Hematology/Oncology Clinics of North America

Volumn 27, Issue 4, 2013, Pages 657-672

  Lazzeroni, Matteo ^a   DeCensi, Andrea ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b GALLIERA HOSPITAL   (Italy)

Author keywords

Aromatase Inhibitors; Aspirin; Breast cancer chemoprevention; Metformin; Selective estrogen receptor modulators

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; EXEMESTANE; LASOFOXIFENE; METFORMIN; PLACEBO; RALOXIFENE; TAMOXIFEN;

CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CATARACT; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FOLLOW UP; FRACTURE; GYNECOLOGIC DISEASE; HEADACHE; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; HYPERTRIGLYCERIDEMIA; INTRADUCTAL CARCINOMA; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; META ANALYSIS; MUSCLE CRAMP; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; VAGINA DISCHARGE; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

AROMATASE INHIBITORS; ASPIRIN; BREAST CANCER CHEMOPREVENTION; METFORMIN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84881274975     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.05.009     Document Type: Review

References (73)

1. American Cancer Society Cancer Facts & Figures 2012 2012, American Cancer Society, Atlanta.
2. Sporn M.B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976, 36:2699-2702.
3. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360:817-824.
4. Cuzick J., Forbes J.F., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I Trial. JNatl Cancer Inst 2007, 99:272-282.
5. Veronesi U., Maisonneuve P., Costa A., et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998, 352:93-97.
6. Veronesi U., Maisonneuve P., Rotmensz N., et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. JNatl Cancer Inst 2007, 99:727-737.
7. Guerrieri-Gonzaga A., Galli A., Rotmensz N., et al. The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives. Ann N Y Acad Sci 2001, 949:113-122.
8. Powles T., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998, 352:98-101.
9. Powles T.J., Ashley S., Tidy A., et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. JNatl Cancer Inst 2007, 99:283-290.
10. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNatl Cancer Inst 1998, 90:1371-1388.
11. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. JNatl Cancer Inst 2005, 97:1652-1662.
12. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361:296-300.
13. Cauley J.A., Norton L., Lippman M.E., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001, 65:125-134.
14. Martino S., Cauley J.A., Barrett-Connor E., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. JNatl Cancer Inst 2004, 96:1751-1761.
15. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. NEngl J Med 2006, 355:125-137.
16. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741.
17. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010, 3:696-706.
18. Cummings S.R., Ensrud K., Delmas P.D., et al. Lasofoxifene in postmenopausal women with osteoporosis. NEngl J Med 2010, 362:686-696.
19. LaCroix A.Z., Powles T., Osborne C.K., et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. JNatl Cancer Inst 2010, 102:1706-1715.
20. Cummings S.R., McClung M., Reginster J.Y., et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. JBone Miner Res 2011, 26:397-404.
21. Powles T.J., Diem S.J., Fabian C.J., et al. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat 2012, 134:299-306.
22. Cuzick J. Aromatase inhibitors for breast cancer prevention. JClin Oncol 2005, 23:1636-1643.
23. Cuzick J., Decensi A., Arun B., et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 2011, 12:496-503.
24. Forbes J.F., Cuzick J., Buzdar A., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53.
25. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 2008, 8:1377-1385.
26. Goss P.E., Qi S., Josse R.G., et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004, 34:384-392.
27. Goss P.E., Ingle J.N., Alés-Martínez J.E., et al. Exemestane for breast-cancer prevention in postmenopausal women. NEngl J Med 2011, 364(25):2381-2391.
28. Cheung A.M., Tile L., Cardew S., et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 2012, 13:275-284.
29. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
30. Decensi A., Gennari A. Insulin breast cancer connection: confirmatory data set the stage for better care. JClin Oncol 2011, 29:7-10.
31. Gunter M.J., Hoover D.R., Yu H., et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. JNatl Cancer Inst 2009, 101:48-60.
32. Gonzalez-Angulo A.M., Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010, 16:1695-1700.
33. Alimova I.N., Liu B., Fan Z., et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest invitro. Cell Cycle 2009, 8:909-915.
34. Ben Sahra I., Regazzetti C., Robert G., et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011, 71:4366-4372.
35. Martin M., Marais R. Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?. JClin Oncol 2012, 30:2698-2700.
36. Decensi A., Puntoni M., Goodwin P., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010, 3:1451-1461.
37. Col N.F., Ochs L., Springmann V., et al. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012, 135(3):639-646.
38. Hadad S., Iwamoto T., Jordan L., et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011, 128:783-794.
39. Jiralerspong S., Palla S.L., Giordano S.H., et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. JClin Oncol 2009, 27:3297-3302.
40. Bonanni B., Puntoni M., Cazzaniga M., et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. JClin Oncol 2012, 30:2593-2600.
41. Chlebowski R.T., McTiernan A., Wactawski-Wende J., et al. Diabetes, metformin, and breast cancer in postmenopausal women. JClin Oncol 2012, 30:2844-2852.
42. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. JNatl Cancer Inst 2007, 99:167-170.
43. Ellis M.J., Tao Y., Luo J., et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. JNatl Cancer Inst 2008, 100:1380-1388.
44. Decensi A., Guerrieri-Gonzaga A., Gandini S., et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol 2010, 22:582-587.
45. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEngl J Med 2002, 346:393-403.
46. Bonora E., Kiechl S., Willeit J., et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998, 47:1643-1649.
47. Goodwin P.J., Stambolic V., Lemieux J., et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011, 126:215-220.
48. Sharma S., Sharma S.C. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems. Indian J Exp Biol 1997, 35:1025-1031.
49. Leahy K.M., Ornberg R.L., Wang Y., et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells invivo. Cancer Res 2002, 62:625-631.
50. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83:493-501.
51. Kaiser J. Wondering how the wonder drug works. Science 2012, 337:1472.
52. Zhao Y., Agarwal V.R., Mendelson C.R., et al. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996, 137:5739-5742.
53. Brueggemeier R.W., Quinn A.L., Parrett M.L., et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999, 140:27-35.
54. Elvin J.A., Yan C., Matzuk M.M. Growth differentiation factor-9 stimulates progesterone synthesis in granulosa cells via a prostaglandin E2/EP2 receptor pathway. Proc Natl Acad Sci USA 2000, 97:10288-10293.
55. Schreinemachers D.M., Everson R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994, 5:138-146.
56. Harris R.E., Namboodiri K., Stellman S.D., et al. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 1995, 24:119-120.
57. Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 1995, 24:107-109.
58. Harris R.E., Kasbari S., Farrar W.B. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999, 6:71-73.
59. Harris R.E., Namboodiri K.K., Farrar W.B. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996, 7:203-205.
60. Coogan P.F., Rao S.R., Rosenberg L., et al. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 1999, 29:72-76.
61. Sharpe C.R., Collet J.P., McNutt M., et al. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000, 83:112-120.
62. Johnson T.W., Anderson K.E., Lazovich D., et al. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002, 11:1586-1591.
63. Paganini-Hill A., Chao A., Ross R.K., et al. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989, 299:1247-1250.
64. Egan K.M., Stampfer M.J., Giovannucci E., et al. Prospective study of regular aspirin use and the risk of breast cancer. JNatl Cancer Inst 1996, 88:988-993.
65. Langman M.J., Cheng K.K., Gilman E.A., et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000, 320:1642-1646.
66. Harris R.E., Chlebowski R.T., Jackson R.D., et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003, 63:6096-6101.
67. Cotterchio M., Kreiger N., Sloan M., et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001, 10:1213-1217.
68. Terry M.B., Gammon M.D., Zhang F.F., et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004, 291:2433-2440.
69. Holmes M.D., Chen W.Y., Li L., et al. Aspirin intake and survival after breast cancer. JClin Oncol 2010, 28:1467-1472.
70. Holmes M.D., Chen W.Y., Schnitt S.J., et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 2011, 130:657-662.
71. Li Y., Brasky T.M., Nie J., et al. Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2012, 21:239-242.
72. Rothwell P.M., Wilson M., Price J.F., et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379:1591-1601.
73. Wald N.J., Morris J.K., Law M.R. Aspirin in the prevention of cancer. Lancet 2011, 377:1649. [author reply: 1651-2].